Pharmacological Modulations of Allergen-Specific Immunotherapy
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
There is mounting evidence that successful allergen immunotherapy (SIT) functions through the
induction of different subset of Treg including Foxp3 positive cells, therefore additional
strategies to enhance this property are highly attractive. Based on previous findings we
assumed that combine allergen immunotherapy with non-specific treatments such as
glucocorticosteroids and vitamin D3 as well as montelukast sodium treatment might enhanced
allergen tolerance induction and improved clinical effectiveness of allergen-specific
immunotherapy
Phase:
Phase 3
Details
Lead Sponsor:
Medical University of Lodz Medical Universtity of Lodz